Kingdon Capital Management’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Kingdon Capital Management’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,403,149	Closed	-$2.38M	–	118
2018 Q3	$2.38M	Hold	1,403,149	–	–	0.17%	93
2018 Q2	$2.44M	Buy	1,403,149 +26,441	+2%	+$45.7K	0.17%	93
2018 Q1	$2.52M	Buy	1,376,708 +335,013	+32%	+$708K	0.2%	91
2017 Q4	$2.32M	Buy	1,041,695 +272,555	+35%	+$678K	0.15%	99
2017 Q3	$2.23M	Sell	769,140 -205,483	-21%	-$701K	0.15%	92
2017 Q2	$4.34M	Sell	974,623 -1,263,078	-56%	-$5.21M	0.3%	73
2017 Q1	$10.4M	Buy	2,237,701 +669,214	+43%	+$3.88M	0.57%	50
2016 Q4	$9.55M	Sell	1,568,487 -69,923	-4%	-$365K	0.46%	66
2016 Q3	$9.03M	Buy	1,638,410 +35,076	+2%	+$164K	0.41%	57
2016 Q2	$6.09M	Buy	+1,603,334	New	+$5.43M	0.34%	70
2016 Q1	–	Sell	-229,420	Closed	-$1.3M	–	150
2015 Q4	$1.3M	Sell	229,420 -110,580	-33%	-$674K	0.06%	108
2015 Q3	$1.8M	Buy	+340,000	New	+$2.63M	0.09%	109

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

OCM

Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Kingdon Capital Management's SGYP Position: Q4 2018 in Review

Kingdon Capital Management sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2018, closing a stake of 1,403,149 shares — an estimated $2.38M sold.

Kingdon Capital Management first reported a position in SGYP in Q3 2015 and held it in 12 quarters. The position peaked at $10.4M in Q1 2017. 89 funds tracked by Wall St. Rank hold SGYP as of Q4 2018.

Kingdon Capital Management reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2018 after selling out during the quarter.
Kingdon Capital Management sold 1,403,149 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2018, an estimated $2.38M.
Kingdon Capital Management first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q3 2015 and held it in 12 quarters.
Kingdon Capital Management's Synergy Pharmaceuticals, Inc Common Stock position peaked at $10.4M in Q1 2017.
89 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2018.

Based on Kingdon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.